Astria Therapeutics Stock Alpha and Beta Analysis
| ATXS Stock | USD 12.95 0.03 0.23% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Astria Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Astria Therapeutics over a specified time horizon. Remember, high Astria Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Astria Therapeutics' market risk premium analysis include:
Beta 0.97 | Alpha 0.9 | Risk 5 | Sharpe Ratio 0.2 | Expected Return 0.99 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Astria Therapeutics Backtesting, Astria Therapeutics Valuation, Astria Therapeutics Correlation, Astria Therapeutics Hype Analysis, Astria Therapeutics Volatility, Astria Therapeutics History and analyze Astria Therapeutics Performance. Astria Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Astria Therapeutics market risk premium is the additional return an investor will receive from holding Astria Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Astria Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Astria Therapeutics' performance over market.| α | 0.90 | β | 0.97 |
Astria Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Astria Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Astria Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Astria Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Astria Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Astria Therapeutics shares will generate the highest return on investment. By understating and applying Astria Therapeutics stock market price indicators, traders can identify Astria Therapeutics position entry and exit signals to maximize returns.
Astria Therapeutics Return and Market Media
The median price of Astria Therapeutics for the period between Sun, Sep 28, 2025 and Sat, Dec 27, 2025 is 12.51 with a coefficient of variation of 17.64. The daily time series for the period is distributed with a sample standard deviation of 2.04, arithmetic mean of 11.54, and mean deviation of 1.63. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | SHAREHOLDER RIGHTS ALERT Halper Sadeh LLC Investigates ATXS and RYN on Behalf of Shareholders | 10/15/2025 |
2 | Why Astria Therapeutics Inc. stock is a value investor pick - Portfolio Update Summary Real-Time Volume Triggers - Fundao Cultural do Par | 10/28/2025 |
3 | Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b2 Trial of Navenibart | 11/06/2025 |
4 | Will Astria Therapeutics Inc. stock split again soon - Fed Meeting Advanced Technical Analysis Signals - newser.com | 11/11/2025 |
5 | Astria Therapeutics Issues Earnings Results | 11/14/2025 |
6 | Is this a good reentry point in Astria Therapeutics Inc. - 2025 Volatility Report Weekly Chart Analysis and Guides - newser.com | 11/18/2025 |
7 | Astria Therapeutics Sees Large Volume Increase - Whats Next - MarketBeat | 12/04/2025 |
8 | Astria Therapeutics, Inc. ATXS Shares Acquired by JPMorgan Chase Co. | 12/10/2025 |
9 | as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily | 12/24/2025 |
About Astria Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Astria or other stocks. Alpha measures the amount that position in Astria Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Current Ratio | 25.13 | 21.73 | 17.49 | 8.98 | Net Debt To EBITDA | 0.37 | 2.11 | 0.58 | 0.61 |
Astria Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Astria Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Astria Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Astria Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Astria Therapeutics. Please utilize our Beneish M Score to check the likelihood of Astria Therapeutics' management manipulating its earnings.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Astria Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Astria Stock Analysis
When running Astria Therapeutics' price analysis, check to measure Astria Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astria Therapeutics is operating at the current time. Most of Astria Therapeutics' value examination focuses on studying past and present price action to predict the probability of Astria Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astria Therapeutics' price. Additionally, you may evaluate how the addition of Astria Therapeutics to your portfolios can decrease your overall portfolio volatility.